List – 31 Biologics Coming Off Patents Between 2022 to 2027
Biologics have been observed to be a rapidly evolving area within biotechnology.
Cancer, autoimmune diseases, and diabetes treatments account for over 60% of the biologics market. Thus making it extremely expensive with prices increasing by the day.
According to the World Health Organization (WHO), these high prices are restricting the healthcare systems from providing affordable, population-wide access to such medicines. This creates a huge space for generic companies to manufacture biosimilars of the originator biologics whose patents have expired.
As a result, generic companies (hey there!) are continuously searching for biologics with a soon-to-be-expired label. To make it easier for them (you), we’ve collated not just the biologics names but also included other information like yearly sales, treatment, dosage, and the brand as well as company names, which could help them (you) easily choose a biologic most profitable to develop a biosimilar.
If you are interested in biologics patents, then you might also be interested in drug patents that are expiring soon. We have a list of drug patents that are expiring between 2026 to 2030. To get the list, please fill out the form below:
So, without any delay, let’s get to the list of biologics patents expiring between 2022-2027.
Biologics Patents Expiration
PERJETA
Pertuzumab
Pertuzumab
Sales:
$4.73 Billion (2021)
$4.73 Billion (2021)
| Patents | Expiration Date |
|---|---|
| US7618631B2 | April 16, 2022 |
| US8337856B2 | September 30, 2023 |
| US7862817B2 | June 1, 2025 |
| US7097840B2 | July 25, 2026 |
Dosage: –
Company: Genentech
Treatment: HER2-positive Breast Cancer
VYROLOGIX
Leronlimab
Leronlimab
Sales:
$576 Million (2020)
$576 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7666419B2 | February 21, 2023 |
| US7851600B2 | February 21, 2023 |
| US7122185B2 | June 1, 2024 |
Dosage: –
Company: Cytodyn Inc.
Treatment: HIV Infection
STELARA
Ustekinumab
Ustekinumab
Sales:
$9.13 Billion (2021)
$9.13 Billion (2021)
| Patents | Expiration Date |
|---|---|
| US7279157B2 | January 13, 2022 |
| US9409984B2 | February 27, 2022 |
| US7166285B2 | May 3, 2022 |
| US8080247B2 | August 2, 2022 |
| US6902734B2 | September 25, 2023 |
Dosage: Injection
Company: Janssen Pharmaceuticals
Treatment: Plaque Psoriasis and Psoriatic Arthritis
BENLYSTA
Belimumab
Belimumab
Sales:
$747 Million (2019)
$747 Million (2019)
| Patents | Expiration Date |
|---|---|
| US7605236B2 | August 5, 2022 |
| US7220840B2 | July 11, 2023 |
| US7879328B2 | July 17, 2023 |
| US7138501B2 | March 9, 2025 |
Dosage: Injection
Company: GlaxoSmithKline
Treatment: Systemic Lupus Erythematosus
CYRAMZA
Ramucirumab
Ramucirumab
Sales:
$1.033 Billion (2020)
$1.033 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US8057791B2 | December 07, 2023 |
| US7498414B2 | January 31, 2026 |
Dosage: –
Company: ImClone Systems Inc.
Treatment: Solid Tumors
ELELYSO
Taliglucerase Alfa
Taliglucerase Alfa
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US8227230B2 | February 24, 2024 |
| US8741620B2 | February 24, 2024 |
| US9220737B2 | February 24, 2024 |
| US7951557B2 | July 01, 2025 |
| US8790641B2 | October 18, 2025 |
Dosage: –
Company: Protalix and Pfizer
Treatment: Type 1 Gaucher disease
IXIARO
Japanese Encephalitis Vaccine
Japanese Encephalitis Vaccine
Sales:
$106.75 Million (2020)
$106.75 Million (2020)
| Patents | Expiration Date |
|---|---|
| US6309650 | December 30, 2022 |
Dosage: Injection
Company: BIKEN and Sanofi Pasteur
Treatment: Japanese encephalitis
JETREA
Ocriplasmin
Ocriplasmin
Sales:
$7.8 Million (2016)
$7.8 Million (2016)
| Patents | Expiration Date |
|---|---|
| US7445775 | October 17, 2026 |
Dosage: Intravitreal Injection
Company: ThromboGenics
Treatment: Symptomatic Vitreomacular Adhesion
KADCYLA
Trastuzumab Emtansine
Trastuzumab Emtansine
Sales:
$960 Million (2018)
$960 Million (2018)
| Patents | Expiration Date |
|---|---|
| US7618631B2 | April 16, 2022 |
| US8337856B2 | September 30, 2023 |
| US7862817B2 | June 1, 2025 |
| US7097840B2 | July 25, 2026 |
Dosage: Intravenous Infusion
Company: Genentech
Treatment: HER2-positive Breast Cancer
KALBITOR
Ecallantide
Ecallantide
Sales:
$67.3 Million (2017)
$67.3 Million (2017)
| Patents | Expiration Date |
|---|---|
| US7276480 | June 6, 2023 |
Dosage: Injection
Company: Takeda Pharmaceutical
Treatment: Hereditary Angioedema
MYALEPT
Metreleptin
Metreleptin
Sales:
$71.4 Million (2018)
$71.4 Million (2018)
| Patents | Expiration Date |
|---|---|
| US8318666B2 | October 22, 2022 |
| US7183254B2 | July 17, 2027 |
Dosage: Injection
Company: Amryt Pharmaceutical
Treatment: Dyslipidemia
NPLATE
Romiplostim
Romiplostim
Sales:
$227 Million (2020)
$227 Million (2020)
| Patents | Expiration Date |
|---|---|
| US6835809 | January 19, 2022 |
Dosage: Injection
Company: Amgen
Treatment: Low blood platelet counts
TANZEUM
Albiglutide
Albiglutide
Sales:
$160 Million (2016)
$160 Million (2016)
| Patents | Expiration Date |
|---|---|
| US7238660B2 | December 23, 2022 |
| US7238667B2 | December 23, 2022 |
| US8071539B2 | December 23, 2022 |
| US9221896B2 | December 23, 2022 |
| US9296809B2 | December 23, 2022 |
| US7977306B2 | January 2, 2023 |
| US7799759B2 | February 11, 2023 |
| US8993517B2 | February 12, 2023 |
| US7189690B2 | October 2, 2023 |
| US7592010B2 | December 1, 2023 |
| US7521424B2 | January 20, 2024 |
| US8287859B2 | February 11, 2024 |
| US8012464B2 | May 21, 2024 |
| US8143026B2 | February 9, 2025 |
| US8211439B2 | April 11, 2025 |
| US7847079B2 | October 4, 2025 |
| US7141547B2 | April 22, 2027 |
Dosage: Injection
Company: GlaxoSmithKline
Treatment: Type 2 Diabetes
VICTOZA
Liraglutide
Liraglutide
Sales:
$2.7 Billion (2018)
$2.7 Billion (2018)
| Patents | Expiration Date |
|---|---|
| US6268343 | August 22, 2022 |
Dosage: Injection
Company: Novo Nordisk
Treatment: Type 2 Diabetes
YERVOY
Ipilimumab
Ipilimumab
Sales:
$1.7 Billion (2020)
$1.7 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US6984720 | February 8, 2022 |
Dosage: Intravenous Infusion
Company: Bristol‑Myers Squibb
Treatment: Melanoma
DARZALEX
Daratumumab
Daratumumab
Sales:
$4.1 Billion (2020)
$4.1 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US7829673B2 | August 27, 2026 |
| US9187565B2 | December 5, 2027 |
Dosage: Intravenous Infusion
Company: Genmab
Treatment: Myeloma
BLINCYTO
Blinatumomab
Blinatumomab
Sales:
$103 Million (2020)
$103 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7635472B2 | November 28, 2025 |
Dosage: Intravenous Infusion
Company: Micromet (acquired by Amgen)
Treatment: Acute Lymphoblastic Leukemia
CIMZIA
Certolizumab Pegol
Certolizumab Pegol
Sales:
$2.04 Billion (2020)
$2.04 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US7186820B2 | February 3, 2022 |
| US7977464B2 | February 13, 2022 |
| US7012135B2 | February 13, 2024 |
Dosage: Subcutaneous Injection
Company: UCB
Treatment: Crohn’s Disease, Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
ILARIS
Canakinumab
Canakinumab
Sales:
$576 Million (2020)
$576 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7446175B2 | December 22, 2022 |
Dosage: Intravenous Infusion
Company: Novartis
Treatment: Systemic Juvenile Idiopathic Arthritis
SIMPONI
Golimumab
Golimumab
Sales:
$576 Million (2020)
$576 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7521206B2 | March 20, 2022 |
| US8241899B2 | November 3, 2022 |
| US7250165B2 | February 3, 2024 |
| US7691378B2 | September 19, 2024 |
Dosage: Subcutaneous Injection
Company: Janssen Biotech
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
TRULICITY
Dulaglutide
Dulaglutide
Sales:
$5.07 Billion (2020)
$5.07 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US10369003B2 | October 15, 2024 |
| US10376376B2 | October 15, 2024 |
| US10610371B2 | October 15, 2024 |
| US11083591B2 | October 15, 2024 |
| US9056018B2 | October 15, 2024 |
| US9867712B2 | October 15, 2024 |
| US10695187B2 | June 28, 2025 |
| US8273854B2 | May 15, 2026 |
| US10130493B2 | July 17, 2026 |
| US8535379B2 | December 13, 2026 |
| US11135072B2 | April 11, 2027 |
| US7452966B2 | December 7, 2027 |
Dosage: Subcutaneous Injection
Company: Eli Lilly and Company
Treatment: Type 2 Diabetes
ZALTRAP
Aflibercept
Aflibercept
Sales:
$15.88 Million (2020)
$15.88 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7399612B2 | November 6, 2023 |
| US7279159B2 | November 11, 2024 |
Dosage: Intravitreal Injection
Company: Regeneron Pharmaceuticals
Treatment: Wet Macular Degeneration and Metastatic Colorectal Cancer
SYLVANT
Siltuximab
Siltuximab
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7612182B2 | October 26, 2022 |
| US7955597B2 | October 26, 2022 |
| US7833786B2 | June 7, 2023 |
| US7291721B2 | September 13, 2027 |
Dosage: Intravenous Infusion
Company: Eusa Pharma
Treatment: Metastatic Renal Cell Cancer, Prostate Cancer, and Castleman’s Disease
LARTRUVO
Olaratumab
Olaratumab
Sales:
$304.7 Million (2018)
$304.7 Million (2018)
| Patents | Expiration Date |
|---|---|
| US8574578B2 | June 19, 2026 |
| US8128929B2 | December 20, 2027 |
Dosage: Intravenous Infusion
Company: Eli Lilly and Company
Treatment: Solid Tumors
OPDIVO
Nivolumab
Nivolumab
Sales:
$7.92 Billion (2020)
$7.92 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US9393301B2 | July 2, 2023 |
| US8168179B2 | July 2, 2023 |
| US9067999B1 | July 2, 2023 |
| US9073994B2 | July 2, 2023 |
| US9439962B2 | July 2, 2023 |
| US9402899B2 | February 5, 2024 |
| US7595048B2 | August 8, 2024 |
| US8728474B2 | August 8, 2024 |
Dosage: Intravenous Infusion
Company: Bristol‑Myers Squibb
Treatment: Different Types of Cancer
PORTRAZZA
Necitumumab
Necitumumab
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US7598350B2 | March 21, 2025 |
Dosage: Intravenous Infusion
Company: Eli Lilly and Company
Treatment: Metastatic Squamous Non-small Cell Lung Cancer
PROLIA
Denosumab
Denosumab
Sales:
$4.6 Billion (2020)
$4.6 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US8409578B2 | June 25, 2022 |
| US8058418B2 | November 30, 2023 |
| US7364736B2 | February 19, 2025 |
Dosage: Subcutaneous Injection
Company: Amgen
Treatment: Osteoporosis
TALTZ
Ixekizumab
Ixekizumab
Sales:
$1.78 Billion (2020)
$1.78 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US8110191B2 | December 5, 2026 |
| US7838638B2 | February 4, 2030 |
Dosage: Subcutaneous Injection
Company: Eli Lilly and Company
Treatment: Autoimmune Diseases
ARANESP
Darbepoetin Alfa
Darbepoetin Alfa
Sales:
$629 Million (2020)
$629 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7217689B1 | May 15, 2024 |
Dosage: Intravenous Infusion
Company: Amgen
Treatment: Anemia
EYLEA
Aflibercept
Aflibercept
Sales:
$8.36 Billion (2020)
$8.36 Billion (2020)
| Patents | Expiration Date |
|---|---|
| US7279159B2 | November 11, 2024 |
Dosage: Intravitreal Injection
Company: Regeneron Pharmaceuticals
Treatment: Wet Macular Degeneration and Metastatic Colorectal Cancer
ARZERRA
Ofatumumab
Ofatumumab
Sales:
–
–
| Patents | Expiration Date |
|---|---|
| US8529902B2 | August 2, 2030 |
Dosage: Intravenous Infusion
Company: Genmab
Treatment: Multiple Sclerosis
Conclusion
Earlier we released a list of 91 drug patents expiring between 2020 to 2022. And while small molecule drugs still dominate the global pharmaceutical market in terms of numbers, many of the most promising new therapies for previously intractable diseases are a result of biologics. Biologics are thus becoming increasingly important to the pharmaceutical market. But having this list is one thing and using it is another.
Developing biosimilars is not going to be as smooth sailing. Generic companies will likely have to face many threats and stiff legal battles depending on the biologic they choose.
With proper threat analysis, companies can save themselves from this torment. Wanna know all about it? Just fill out the form below and we’ll get back to you in no time.
List curated by: Divya Goyal, Life Science Team Authored By: Nidhi, Marketing.
-
[…] protection for several years. That means it is not subject to generic competition. But in 2023, JNJ loses patent protection on Stelara, which was responsible for approximately $9 billion in sales in 2021. […]
[…] as high as $80 billion. The stimulus of expiring patents will continue to prompt development as 31 Biologics patents are slated to expire in that same time frame. These considerations will continue to push […]
Leave a Comment
It is always impressive to see how the FDA has, in it’s fundamental values, the value of sharing information and making it accessible, for and to the public.